H.C. Wainwright analyst Ananda Ghosh raised the firm’s price target on Structure Therapeutics (GPCR) to $90 from $60 and keeps a Buy rating on the shares. The firm says its key opinion leader feedback validates the company’s titration strategy. With oral GLP-1s set to become “Tier 1 therapies” driven by payer economics, Structure’s current valuation offers a “massive arbitrage opportunity relative to recent deal metrics with a strong M&A potential,” the analyst tells investors in a research note. H.C. Wainwright views the company’s recent Phase 2 data as encouraging.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GPCR:
- Structure Therapeutics announces initiation of Phase 1 study of ACCG-2671
- Structure Therapeutics price target raised to $125 from $120 at Morgan Stanley
- Structure Therapeutics price target raised to $120 from $87 at Citizens
- Structure Therapeutics price target raised to $125 from $79 at Jefferies
- Structure Therapeutics Announces $650 Million Public Offering